COVID-19 Coronavirus


COVID-19 Coronavirus Travel and Policy Updates | This page was updated April 27, 2020

Dear Customers, Vendors and Employees:

The safety and wellbeing of our employees remain a top priority at Selexis, particularly concerning the coronavirus (COVID-19) and precautionary measures. We also remain committed to providing you with information on what we are doing to respond to the emerging situation. Our entire leadership team is focused on monitoring the coronavirus issue and ensuring we are taking the necessary steps for business continuity. We continue to pay close attention to communications from government agencies as well as the World Health Organization and the Swiss Federal Office of Public Health (FOPH).

Selexis is here to support the global research community working on COVID-19: The Selexis team is here to support you and the biopharmaceutical industry in its effort to develop ways to both prevent and address SARS-CoV-2, the virus causing COVID-19. To date, we are receiving supplies and fulfilling orders, and our Operations team is on the phone regularly with our suppliers and shipping companies. In addition, our Business Development team is actively discussing new projects – with a particular focus on manufacturing monoclonal antibodies (mAbs) and vaccines designated to address the global public health crisis as a result of COVID-19.

April 27, 2020 Update

  • Based on information from government agencies, Selexis has lowered the pandemic response to Phase 3 Local.
  • To date (April 27, 2020) we have one employee quarantined.
  • Currently we are sending and receiving all shipments for cell line development services. We are in close communications with shipping logistics and our vendors.
  • As of April 27:
    • Following rules mandated by the Cantonal Government in Switzerland, we have implemented a ramp-up plan that will allows us to be at 100% activity.
    • To further strengthen safety measures and create a safer environment for our employees, Selexis has required everyone, including visitors, to wear a surgical mask while at our facilities.
    • Employee Travel
      • Physical participation in all conferences is canceled through August 30, 2020.
      • All international business travel will require CEO’s approval in advance.
      • For personal travel (including between countries in Europe), employees should inform their supervisor and copy behealthy@selexis.com. This excludes border crossing to and from the Selexis headquarters in Switzerland and the Great Geneva Area (100 km from Geneva).

 

April 14, 2020 Update

  • To date (April 14, 2020) we have one employee quarantined.
  • Currently we are sending and receiving all shipments for cell line development services. We are in close communications with shipping logistics and our vendors.
  • As of April 7:
    • We are following guidelines mandated by the Swiss and State Government ensuring all onsite employees are given enough working space.
    • To further strengthen safety measures and create a safer environment for our employees, Selexis has required everyone to wear a surgical mask while working at our facilities. Hydroalcoholic gel is also provided on each laboratory and office desk.
    • Employee Travel
      • Physical participation in all conferences is canceled through August 30, 2020.
      • All international business travel will require CEO’s approval in advance.
      • For personal travel (including between countries in Europe), employees should inform their supervisor and copy behealthy@selexis.com. This excludes border crossing to and from the Selexis headquarters in Switzerland and the Great Geneva Area (100 km from Geneva).

 

March 16, 2020 Update

  • To date (March 16, 2020), while we presently have no employees with symptoms associated with COVID-19, we have raised our pandemic phase to Level 6 – High Impact. The has been done as a prophylactic measure to ensure the health and safety of our employees and continued laboratory operations.
  • Regarding our ongoing operations, in the interest of ensuring employee safety while maintaining business continuity, we are reorganizing laboratory and business operations with a balance of structured onsite laboratory shifts and remote, work-from-home practices.
  • From a supply chain perspective, we currently have sufficient supplies to support current and new programs for the next quarter.
  • Currently we are sending and receiving all shipments for cell line development services. We are in close communications with shipping logistics and our vendors.
  • As of March 13, on-site visitors are restricted except for essential contractors.
  • For personal travel (including between countries in Europe), employees should inform their supervisor and copy behealthy@selexis.com. This excludes border crossing to and from the Selexis headquarters in Switzerland and the Great Geneva Area (100 km from Geneva).
  • Personal and business travel is prohibited to the areas designated by CDC (https://wwwnc.cdc.gov/travel/notices) or local country government as high-risk (including China, Japan, South Korea, Venezuela, Italy).
  • All international business travel will require CEO’s approval in advance.
  • Participation in all conferences is canceled through May 31.

 

March 10, 2020 Update

  • Based on information from government agencies, Selexis has raised the pandemic response to Phase 3 Local.
  • Travel to China, Hong Kong, Macau, South Korea and Italy is prohibited.
  • Selexis continues to monitor industry conferences for cancellations and/or travel restrictions.

 

March 6, 2020 Update

  • Based on information from government agencies, Selexis initiated its Pandemic Response Plan.
  • The organizers of BIO-Europe Spring in Paris have announced they will hold the conference in a digital format. Selexis employees will not be traveling to Paris for the meeting.  LEARN MORE

 

March 5, 2020 Update

  • Travel to China, Hong Kong, Macau and South Korea is prohibited.
  • Travel to Japan or Italy requires prior approval from the Selexis CEO.
  • Anyone traveling internationally on non-Selexis business reasons (i.e. vacation) must inform their management of their plans and will be handled on a case by case basis.
  • At this time, all other required travel is permitted.

 

For any additional questions or concerns, please contact Robert Meister at robert.meister@selexis.com.

RESOURCES